CCNU for the treatment of dogs with histiocytic sarcoma

Katherine A Skorupski, Craig A. Clifford, Melissa C. Paoloni, Ana Lara-Garcia, Lisa Barber, Michael S Kent, Amy K. LeBlanc, Aarti Sabhlok, Elizabeth A. Mauldin, Frances S. Shofer, C. Guillermo Couto, Karin U. Sørenmo

Research output: Contribution to journalArticle

96 Scopus citations

Abstract

Background: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. Hypothesis: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. Animals: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. Methods: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. Results: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (<100,000 platelets/μL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of <1 month survival. Conclusions and Clinical Importance: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalJournal of Veterinary Internal Medicine
Volume21
Issue number1
DOIs
StatePublished - Jan 2007

    Fingerprint

Keywords

  • CD18
  • Dendritic cell neoplasia
  • Lomustine
  • Malignant histiocytosis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Skorupski, K. A., Clifford, C. A., Paoloni, M. C., Lara-Garcia, A., Barber, L., Kent, M. S., LeBlanc, A. K., Sabhlok, A., Mauldin, E. A., Shofer, F. S., Couto, C. G., & Sørenmo, K. U. (2007). CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine, 21(1), 121-126. https://doi.org/10.1892/0891-6640(2007)21[121:CFTTOD]2.0.CO;2